FDA clears first over-the-counter glucose monitor for children

A glucose monitor that once required a prescription and was aimed at adults is now heading into children’s backpacks, medicine cabinets and school-day routines. The U.S. Food and Drug Administration on June 12 cleared Dexcom’s Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children 2 and older who do not use insulin. The decision broadens a consumer device first cleared for adults in March 2024 and could push glucose tracking beyond diagnosed diabetes and into routine family monitoring.

The clearance matters most for families trying to understand early metabolic risk before diabetes develops. The FDA said prediabetes is increasingly affecting children in the United States, and Michelle Tarver, director of the agency’s Center for Devices and Radiological Health, said the move reflects a commitment to innovation for pediatric patients and to safe, effective device use in the places where children live, learn and play. In practical terms, Stelo is a sensor inserted under the skin that sends glucose readings to a mobile app, giving parents and clinicians a tool that can be used without filling a prescription for each purchase.

That ease of access is also where the clinical questions begin. Continuous glucose monitoring can provide real-time signals about food, activity and glucose swings, but the value of those readings depends on whether families know how to interpret them. For children who do not use insulin, the monitor may be most useful as an early-warning tool for kids at risk of prediabetes or type 2 diabetes, not as a stand-alone diagnosis. Without medical guidance, the same data could also create confusion, anxiety or unnecessary changes in diet and behavior.

The broader public health backdrop is large enough to make the FDA’s bet understandable. The Centers for Disease Control and Prevention says 115.2 million Americans have prediabetes, and more than 40 million people in the United States have diabetes. The American Diabetes Association says more than 40 million children and adults in the United States have diabetes, underscoring the scale of the market if consumer monitoring continues to spread.

The Stelo decision also fits a larger shift in pediatric metabolic care, where regulators have been widening treatment options earlier in the disease process. Recent FDA actions have expanded diabetes medicines for children, including oral drugs for children 10 and older. For Dexcom, the new pediatric indication does not create a new product so much as a larger audience for one already sold over the counter. For families, it may offer a simpler way to watch glucose trends. The unanswered question is whether easier access will improve prevention, or only make more children and parents stare at numbers that still need a doctor’s context.